High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

Episode 3 March 16, 2022 00:19:56
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3
COR2ED Medical Education
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

Mar 16 2022 | 00:19:56

/

Show Notes

COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

Other Episodes

Episode 1

March 08, 2022 00:38:59
Episode Cover

Prostate Cancer Highlights from ASCO GU 2022

COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and...

Listen

Episode 14

June 20, 2023 00:23:12
Episode Cover

Breast Cancer : Oral SERDs in ER+ breast cancer. Episode 1 - efficacy and safety and treatment landscape

COR2ED Medical Education: In this podcast, the experts give an overview of  the EMERALD trial  and present elacestrant as the first, and currently only,...

Listen

Episode 21

September 03, 2023 00:29:25
Episode Cover

Advanced HCC: 2nd line treatment selection and the right time to switch

COR2ED Medical Education: Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at...

Listen